II. Pathophysiology
- Natural host species (e.g. animal carcasses, infected bats) are specific to certain geographic regions
- Natural outbreaks typically start in these regions
- However, person to person spread may occur in new regions if patients travel
- Responsible for most cases in humans
- Transmission
- Natural exposure to body fluids
- Bioterrorism exposure to aerosolized infectious agent
- Pathogenesis
- All Viral Hemorrhagic Fevers result in vascular endothelial damage
- Results in Flushing, edema, Petechiae, Ecchymosis, Hemorrhage and shock
- All Viral Hemorrhagic Fevers result in vascular endothelial damage
III. Causes
- Background
- Four families of lipid-enveloped single-stranded RNA viruses
- Arena Virus (Arenaviridae, Rodent Reservoir)
- Lassa Fever
- Junin
- Machupo
- Lujo
- Sabia
- Chapare
- Bunyavirus (Bunyaviridae)
- Rift Valley Fever
- Crimean Congo Hemorrhagic FeverVirus
- Hantavirus Hemorrhagic Fever
-
Flavivirus (Flaviviridae)
- Yellow Fever
- Dengue Fever
- Omsk Hemorrhagic Fever
- Kyasanur Forest Disease
- Filovirus (Filoviridae, Bat Reservoir)
IV. Findings
- Incubation: 2-21 days
- Non-specific symptoms (initial phase)
- Fever
- Headache
- Myalgias
- Arthralgias
- Rash
- Gastrointestinal symptoms (second phase)
- Bleeding
- Conjunctival Injection
- Mucosal Bleeding (gums, Gastrointestinal Tract)
- Hemoptysis
- Epistaxis
- Hemoptysis
- Bloody Diarrhea
- Petechiae, Purpura and Ecchymosis
- Other late findings
- Shock with Multisystem organ failure
- Encephalitis
V. Diagnosis: Hemorrhagic Fever Syndrome (WHO)
- Fever <3 weeks AND
- Severely ill patient AND
- Two hemorrhagic findings (without known host predisposing factors)
- Hemorrhagic or Purpuric rash
- Epistaxis
- Hematemesis
- Hemoptysis
- Blood in stools
VI. Labs
- Diagnostic specimens are sent to specialized labs (e.g. CDC or U.S. Army Medical Research Institute of Infectious Diseases)
VII. Complications
- Multiorgan Failure
- Hepatic Failure
- Renal Failure
- Hemorrhagic Shock
- Septic Shock
VIII. Management: General
- See Specific causes
- Strict patient isolation
- Supportive care
-
Antiviral management
- Ribavirin (see below)
- Monoclonal Antibody treatments have been developed for several hemorrhagic fevers
- See Ebola
-
Personal Protective Equipment for care givers
- Transmission from the body fluids (percutaneous, mucosal contact) is common at the end stages of the disease
- See Personal Protection Equipment for protection against Viral Hemorrhagic Fevers
- See Donning and Doffing PPE
- Disinfection with dilute bleach
- Use 1:10 bleach solution to disinfect bodies and excretions
- Use 1:100 bleach solutions to disinfect surfaces, equipment, bedding and reusable PPE
IX. Management: Ribavirin (Virazole)
- Indications
- Lassa Fever
- Arenaviridae
- Bunyaviridae
- May be used in other Viral Hemorrhagic Fevers (e.g. ebola)
-
Ribavirin Protocol
- Load 30 mg/kg (up to 2 g) IV
- Then 16 mg/kg (up to 1 g) IV every g hours for 4 days
- Then 8 mg/kg (up to 500 mg) IV every 8 hours for 6 days
X. References
- Black, Martin, DeVos (2018) Crit Dec Emerg Med 32(8): 3-12
- Charbonnet and Mace (2023) Crit Dec Emerg Med 37(4): 4-10
- Gladwin (2014) Clinical Microbiology, MedMaster, Miami, p.306-7, 398
- Rathjen (2021) Am Fam Physician 104(4): 376-85 [PubMed]